-
Click for More Details.OrigiMed and Takeda Announced Partnership to Accelerate R&D and Commercialization of Innovative MedicinesOrigiMed, a China-based leading precision medicine company and Takeda, a global biopharmaceutical company announced their strategic partnership to develop a genomic-based precision medicine platform during the 3rd China International Import Expo.
2020-11-11 -
Click for More Details.Bayer and OrigiMed reached a partnership to develop a next generation sequencing (NGS) based companion diagnostic-in vitro diagnostic (CDx-IVD) product in China for Larotrectinib, for NTRK gene fusion detectionBayer and OrigiMed (Shanghai) Co., Ltd. (referred to as "OrigiMed") today announced a strategic collaboration for the development and commercialization of NGS-based companion diagnostics – in vitro diagnostic (CDx-IVD) in China for detection of NTRK gene fusions.
2020-04-30 -
Click for More Details.CTONG-OrigiMed New Clinical Trial Sharing Platform Launched during the 3rd OrigiMed Summit for Cancer DiscoveryWith fast advances in the medical industry, on May 11, 2019, the third OrigiMed Summit for Cancer Discovery: Immunotherapy and Targeted Therapy was successfully held in Guangzhou.
2019-05-24 -
Click for More Details.OrigiMed Completes Series B Round Focusing on Creating a Comprehensive Precision Medicine Platform for OncologyOrigiMed (Shanghai) Co., Ltd., (OrigiMed) has formally announced the completion of its Series B financing.
2019-01-04 -
Click for More Details.Launch of Special Chinese Big Data Platform for Cancer Genomics Informatics to Accelerate Innovation and Development of China's Precision Diagnosis and TreatmentOn September 21, 2018, the CSCO precision medicine international session with the theme of "All-Round Research by Experts for Further Study", hosted by the Chinese Society of Clinical Oncology (CSCO) and organized solely by OrigiMed Co., Ltd.
2018-09-28
All rights reserved in © Copyright 2022 OrigiMed Ltd
